Literature DB >> 19942149

Lithium and thyroid.

John H Lazarus1.   

Abstract

One in 200 people receive lithium for treatment of bipolar disorder. The common clinical side effects of the drug are goitre in up to 40% and hypothyroidism in about 20%. Lithium increases thyroid autoimmunity if present before therapy. Treatment with levothyroxine is effective and lithium therapy should not be stopped. Lithium may cause hyperthyroidism due to thyroiditis or rarely Graves' disease. As lithium inhibits thyroid hormone release from the thyroid gland it can be used as an adjunct therapy in the management of severe hyperthyroidism. It also increases thyroidal radioiodine retention and may be effective in reducing administered activity in hyperthyroidism. There is no clinical benefit of lithium therapy in thyroid cancer. More research is required on the cellular proliferative effects of lithium as well as its impact on the immune system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19942149     DOI: 10.1016/j.beem.2009.06.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  42 in total

Review 1.  Paradoxical and bidirectional drug effects.

Authors:  Silas W Smith; Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

2.  Dietary intake and plasma metabolomic analysis of polyunsaturated fatty acids in bipolar subjects reveal dysregulation of linoleic acid metabolism.

Authors:  Simon J Evans; Rachel N Ringrose; Gloria J Harrington; Peter Mancuso; Charles F Burant; Melvin G McInnis
Journal:  J Psychiatr Res       Date:  2014-06-12       Impact factor: 4.791

Review 3.  Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?

Authors:  Gabriele Sani; Giulio Perugi; Leonardo Tondo
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

4.  Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum.

Authors:  Alex Stagnaro-Green; Marcos Abalovich; Erik Alexander; Fereidoun Azizi; Jorge Mestman; Roberto Negro; Angelita Nixon; Elizabeth N Pearce; Offie P Soldin; Scott Sullivan; Wilmar Wiersinga
Journal:  Thyroid       Date:  2011-07-25       Impact factor: 6.568

Review 5.  Management of adverse effects of mood stabilizers.

Authors:  Andrea Murru; Dina Popovic; Isabella Pacchiarotti; Diego Hidalgo; Jordi León-Caballero; Eduard Vieta
Journal:  Curr Psychiatry Rep       Date:  2015-08       Impact factor: 5.285

6.  Endocrine disruption as an adverse effect of non-endocrine targeting pharmaceuticals.

Authors:  Shakila Sabir; Muhammad Furqan Akhtar; Ammara Saleem
Journal:  Environ Sci Pollut Res Int       Date:  2018-11-22       Impact factor: 4.223

7.  Development of Graves' disease after long-standing hypothyroidism on treatment, with acute toxicity to thionamides and lithium.

Authors:  Yashdeep Gupta; Sandeep Singh; Ariachery C Ammini
Journal:  BMJ Case Rep       Date:  2012-08-01

8.  Lithium-induced transient euthyroid hyperthyroxinemia: a case report.

Authors:  Lakshminarayana Chekuri; Jaquelyn R Lange; Purushottam B Thapa
Journal:  Prim Care Companion CNS Disord       Date:  2014

9.  Epigenetic programming alterations in alligators from environmentally contaminated lakes.

Authors:  Louis J Guillette; Benjamin B Parrott; Eric Nilsson; M M Haque; Michael K Skinner
Journal:  Gen Comp Endocrinol       Date:  2016-04-11       Impact factor: 2.822

Review 10.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.